Skip to main content
Log in

Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus

Clinical Rheumatology Aims and scope Submit manuscript

Summary

In order to investigate, if complement levels can be used as an indicator of clinical activity in systemic lupus erythematosus (SLE), levels of C3, C4, CH50, and C3d were measured in 79 patients, 41 with inactive, 31 with moderately active and 7 with severely active disease. Our study shows that C3d, and particularly the C3d/C3 ratio, provide sensitive markers for disease activity in SLE. Since C3d is a direct measurement of complement turnover, it reflects complement activation better than C3, C4 and CH50.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bourke, B.E., Moss, I.K., Maini, R.N. Measurement of the complement C3 breakdown product C3d by rocket immunoelectropheresis. J Immunol Methods 1982, 48, 97.

    Article  PubMed  Google Scholar 

  2. Brandslund, I., Sierstedt, H.C., Svehag, S.-E., Teisner, B. Double-decker-rocket immunoelectrophoresis for direct quantification of complement C3 split products with C3d specificities in plasma. J Immunol Methods 1981, 44, 63.

    Article  PubMed  Google Scholar 

  3. Charlesworth, J.A., Williams, D.G., Sherington, E., Lachmann, P.J., Peters, D.K. Metabolic studies of the third component of complement and the glycine-rich beta-glycoprotein in patients with hypocomplementemia. J Clin Invest 1974, 53, 1578–1587.

    PubMed  Google Scholar 

  4. Clough, J.D., Chang, R.K. Effectiveness of testing for anti-DNA and the complement components iC3b, Bb, and C4 in the assessment of activity of systemic lupus erythematosus. J Clin Lab Anal 1990, 4, 268–273.

    PubMed  Google Scholar 

  5. Gewurz, H., Suyehira, L.A. Complement and immune complexes. In: Manual of Clinical Immunology, 2nd ed., Ed.: Roese, N., Friedmann, H., Washington, Am Soc Microbiol, 1980.

    Google Scholar 

  6. Hartung, K., Fontana, A., Klar, M., Krippner, H., Jörgens, K., Lang, B., Peter, H.H., Pichler, W.J., Schendel, D., Robin-Winn, M., Deicher, H. Association of class I, II, and III MHC gene products with systemic lupus erythematosus. Results of a Central European Multicenter Study. Rheumatol Int 1989, 9, 13–18.

    Article  PubMed  Google Scholar 

  7. Hopkins, P., Belmont, H.M., Buyon, J., Phillips, M., Weissmann, G., Abramson, S.B. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988, 31, 632.

    PubMed  Google Scholar 

  8. Inman, R.D., Fong, J.K.K., Pussell, B.A., Ryan, P.J., Hughes, G.R.V. The C1q binding assay in systemic lupus erythematosus: discordance with disease activity. Arthritis Rheum 1980, 23, 1282–1286.

    PubMed  Google Scholar 

  9. Isenberg, D.A., Colaco, C.B., Dudeney, C., Todd-Pokropek, A., Snaith, M.L. The relationship of anti-DNA antibody idiotypes and anti-cardiolipin antibodies to disease activity in systemic lupus erythematosus. Medicine (Baltimore) 1986, 65, 46–55.

    PubMed  Google Scholar 

  10. Isenberg, D.A., Shoenfeld, Y., Schwartz, R.S. Multiple serological reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum 1984, 27, 132–138.

    PubMed  Google Scholar 

  11. Kerr, L.D., Adelsberg, B.R., Schulman, P., Spiera, H. Faktor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum 1989, 32, 1406–1413.

    PubMed  Google Scholar 

  12. Kingsmore, S.F., Thompson, J.M., Crockard, A.D., Todd, D., McKirgan, J., Patterson, C., Fay, A.C., McNeill, T.A. Measurement of circulating immune complexes containing IgG, IgM, IgA and IgE by flox cytometry: correlation with disease activity in patients with systemic lupus erythematosus. J Clin Lab Immunol 1989, 30, 45–52.

    PubMed  Google Scholar 

  13. Morrow, W.J.W., Isenberg, D.A., Todd-Pokropek, A., Perry, H.F., Snaith, M.L. Useful laboratory measurements in the management of systemic lupus erythematosus and rheumatoid arthritis. Q J Med 1982, 51, 125–138.

    PubMed  Google Scholar 

  14. Morrow, W.J.W., Williams, D.J.P., Ferec, C., et al., The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1983, 42, 668–671.

    PubMed  Google Scholar 

  15. Negoro, N., Okamura, M., Takeda, T., Koda, S., Amatsu, K., Inoue, T., Curd, J.G., Kanayama, Y. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus. Arthritis Rheum 1989, 32, 1233–1242.

    PubMed  Google Scholar 

  16. Nürnberger, W., Link, P., Becker, H., Helmke, K., Wahn, V., Dreher, R. Korrelation der C3dg/C3-Ratio zur Krankheitsaktivität beim systemischen lupus erythematosus. Aktuel Rheumatol 1988, 13, 179–182.

    Google Scholar 

  17. Perrin, L.H., Lambert, P.H., Miescher, P.A. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 1975, 56, 165–176.

    PubMed  Google Scholar 

  18. Sekita, K., Doi, T., Muso, E., Yoshida, H., Kanatsu, K., Hamashima, Y. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus. Clin Exp Immunol 1984, 55, 487–494.

    PubMed  Google Scholar 

  19. Stannat, S., Bahlmann, J., Kiessling, D., Koch, K.-M., Deicher, H., Peter, H.H. Complement activation during hemodialysis. Contrib Nephrol 1985, 46, 102–108.

    PubMed  Google Scholar 

  20. Swaak, A.J., Aarden, L.A., Statius van Eps, L.W., Feltkamp, T.E.W. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979, 22, 226–235.

    PubMed  Google Scholar 

  21. Swaak, A.J., Groenwold, J., Aarden, L.A. Statius van Eps, L.W., Feltkamp, T.E.W. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis 1982, 41, 388–395.

    PubMed  Google Scholar 

  22. Swaak, A.J., Groenwold, J., Hannema, A., Hack, C.E. Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3d) in patients with systemic lupus erythematosus. A prospective study. Rheumatol Int 1985, 5, 215–220.

    Article  PubMed  Google Scholar 

  23. Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., Schaller, J.G., Talal, N., Winchester, R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25, 1271.

    PubMed  Google Scholar 

  24. Ter Borg, E.J., Horst, G., Hummel, E.J., Limburg, P.C., Kallenberg, C.G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990, 33, 634–643.

    PubMed  Google Scholar 

  25. Valentijn, R.M., Van Overhagen, H., Hazevoet, H.M., et al., The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1985, 28, 904–913.

    PubMed  Google Scholar 

  26. Wild, G., Watkins, J., Ward, A.M., Hughes, P., Hume, A., Rowell, N.R. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol 1990, 80, 167–170.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Röther, E., Lang, B., Coldewey, R. et al. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 12, 31–35 (1993). https://doi.org/10.1007/BF02231555

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02231555

Key words

Navigation